Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2006 3
2007 5
2008 1
2010 2
2012 1
2014 1
2015 1
2016 2
2017 1
2020 1
2021 1
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Exploiting Preexisting Immunity to Enhance Oncolytic Cancer Immunotherapy.
Tähtinen S, Feola S, Capasso C, Laustio N, Groeneveldt C, Ylösmäki EO, Ylösmäki L, Martins B, Fusciello M, Medeot M, Tagliamonte M, Chiaro J, Hamdan F, Peltonen K, Ranki T, Buonaguro L, Cerullo V. Tähtinen S, et al. Among authors: ranki t. Cancer Res. 2020 Jun 15;80(12):2575-2585. doi: 10.1158/0008-5472.CAN-19-2062. Epub 2020 Feb 27. Cancer Res. 2020. PMID: 32107211
Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform.
Ylösmäki E, Ylösmäki L, Fusciello M, Martins B, Ahokas P, Cojoc H, Uoti A, Feola S, Kreutzman A, Ranki T, Karbach J, Viitala T, Priha P, Jäger E, Pesonen S, Cerullo V. Ylösmäki E, et al. Among authors: ranki t. Mol Ther Oncolytics. 2021 Feb 10;20:459-469. doi: 10.1016/j.omto.2021.02.006. eCollection 2021 Mar 26. Mol Ther Oncolytics. 2021. PMID: 33718594 Free PMC article.
Retrospective, Registry-based, Cohort Investigation of Clinical Outcomes in Patients with Cutaneous Squamous Cell Carcinoma and Basal Cell Carcinoma in Finland.
Tuominen S, Ukkola-Vuoti L, Riihilä P, Knuutila JS, Kähäri VM, Lassenius M, Ranki T, Pousar K, Vassilev L, Vuoti S, Mattila K. Tuominen S, et al. Among authors: ranki t. Acta Derm Venereol. 2022 Apr 8;102:adv00693. doi: 10.2340/actadv.v102.2073. Acta Derm Venereol. 2022. PMID: 35356995 Free PMC article.
Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8+ T-cell response, prominent infiltration of CD8+ lymphocytes and Th1 type polarization.
Ranki T, Joensuu T, Jäger E, Karbach J, Wahle C, Kairemo K, Alanko T, Partanen K, Turkki R, Linder N, Lundin J, Ristimäki A, Kankainen M, Hemminki A, Backman C, Dienel K, von Euler M, Haavisto E, Hakonen T, Juhila J, Jaderberg M, Priha P, Vassilev L, Vuolanto A, Pesonen S. Ranki T, et al. Oncoimmunology. 2014 Dec 15;3(10):e958937. doi: 10.4161/21624011.2014.958937. eCollection 2014 Nov. Oncoimmunology. 2014. PMID: 25941579 Free PMC article.
Tissue-specific promoters active in CD44+CD24-/low breast cancer cells.
Bauerschmitz GJ, Ranki T, Kangasniemi L, Ribacka C, Eriksson M, Porten M, Herrmann I, Ristimäki A, Virkkunen P, Tarkkanen M, Hakkarainen T, Kanerva A, Rein D, Pesonen S, Hemminki A. Bauerschmitz GJ, et al. Among authors: ranki t. Cancer Res. 2008 Jul 15;68(14):5533-9. doi: 10.1158/0008-5472.CAN-07-5288. Cancer Res. 2008. PMID: 18632604
Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers.
Ranki T, Pesonen S, Hemminki A, Partanen K, Kairemo K, Alanko T, Lundin J, Linder N, Turkki R, Ristimäki A, Jäger E, Karbach J, Wahle C, Kankainen M, Backman C, von Euler M, Haavisto E, Hakonen T, Heiskanen R, Jaderberg M, Juhila J, Priha P, Suoranta L, Vassilev L, Vuolanto A, Joensuu T. Ranki T, et al. J Immunother Cancer. 2016 Mar 15;4:17. doi: 10.1186/s40425-016-0121-5. eCollection 2016. J Immunother Cancer. 2016. PMID: 26981247 Free PMC article.
Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8+ T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer.
Vassilev L, Ranki T, Joensuu T, Jäger E, Karbach J, Wahle C, Partanen K, Kairemo K, Alanko T, Turkki R, Linder N, Lundin J, Ristimäki A, Kankainen M, Hemminki A, Backman C, Dienel K, von Euler M, Haavisto E, Hakonen T, Juhila J, Jäderberg M, Priha P, Vuolanto A, Pesonen S. Vassilev L, et al. Among authors: ranki t. Oncoimmunology. 2015 Apr 1;4(7):e1017702. doi: 10.1080/2162402X.2015.1017702. eCollection 2015 Jul. Oncoimmunology. 2015. PMID: 26140248 Free PMC article.
23 results